CRUK Combinations Alliance are pleased to announce that a new agent from Astex Pharmaceuticals is on offer to the ECMC Network. ASTX660 is a Dual Inhibitor of Apoptosis Proteins (XIAP and cIAP1). We invite researchers to submit proposals involving the novel agent in combination.
Key dates and details of the agent, including preclinical combination data, are available on our website and attached. To get involved, please complete and submit the EOI form (attached) to CombinationsAlliance@cancer.org.uk by 11th July.
We encourage attendance at the webinar taking place on 26th April at 16:00 (UK time) in which more data about ASTX660 will be discussed.
We look forward to hearing from you,
The Combinations Alliance team